Fundraising FoxPhaseBio Pharmaceuticals
Malvern, US · Delaware corporation · 7 known investors
Find your way into PhaseBio Pharmaceuticals
Sign up to see every warm intro you have to PhaseBio Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the PhaseBio Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
PhaseBio is a company focused on developing treatments for cardiovascular disease, which is a leading cause of death in the United States.
Founders & leadership
AC
Ashutosh ChilkotiFounder
JS
Joel SussmanExecutive
JM
Jonathan MowChief Executive OfficerMow joined PhaseBio as Chief Business Officer in 2012 and led the company as CEO from 2015 to 2023, later serving as Chief Executive Officer of VERALOX Therapeutics. His earlier career included VP of Business Development at Amylin Pharmaceuticals, co-founding Corus Pharma, where he was VP of Commercial and Business Development, and roles at PathoGenesis, Bristol Myers Squibb, and Lederle International.
Board
JB
James BarrettBoard director
MG
Michael GutchBoard director
JK
Justin KleinBoard director
AK
Asish K. XavierBoard director
CT
Clay ThorpBoard directorAdvisory Board; General Partner & Co-Founder, Hatteras Venture Partners at Blackbird Bioventures
GF
Guy FishBoard director
RI
Investors · 7
Mountain Group Capitallisted by Mountain Group CapitalNashville
How we know: Mountain Group Capital's portfolio page · Not right? Tell us
New Enterprise Associates (NEA)listed by New Enterprise Associates (NEA)Menlo Park · $200K – $40M
How we know: funding news · biospace.com · Not right? Tell us
Hatteras Venture PartnersreportedResearch Triangle · $500K – $4Mvia Clay Thorp · board
How we know: a partner's Signal profile · board seat on SEC Form D · biospace.com · the VCSheet dataset · Not right? Tell us
Johnson & Johnson Innovation – JJDCreportedNew Brunswick
How we know: a partner's Signal profile · Not right? Tell us
Also in the syndicate · 3
Fletcher Spaght VenturesJohnson & Johnson Development CorporationOSI Investment Holdings (now Astellas Venture Management)
Funding
SEC filings, press & company announcements$53.6M disclosed across 3 of 5 rounds · 2012–2018
- Undisclosed amountSeries BJun 2012
New Enterprise Associates (lead), Fletcher Spaght Ventures, Hatteras Venture Partners, Johnson & Johnson Development Corporation, OSI Investment Holdings (now Astellas Venture Management)
Source ↗
▶$26MraisedSep 2018 · 20 investors · PharmaceuticalsRule 506(b)
▶$26MraisedSep 2018 · 20 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan MowExecutive Officer, Director
- Linda TuftsDirector
- Justin KleinDirector
- Clay ThorpDirector
- Bibhash MukhopadhyayDirector
- John SharpExecutive Officer
- Nancy HutsonDirector
- Caroline LoewyDirector
- Tyrell RiversDirector
- Offering amount
- $32.1M
- Amount sold
- $26M
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.6MraisedJan 2017 · 9 investors · BiotechnologyRule 506(b)
▶$6.6MraisedJan 2017 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael GutchDirector
- James BarrettDirector
- Jonathan MowExecutive Officer, Director
- Justin KleinDirector
- Ashutosh ChilkotiDirector
- Guy FishDirector
- Clay ThorpDirector
- Asish K. XavierDirector
- Robert IngramDirector
- John SharpExecutive Officer
- Offering amount
- $7.9M
- Amount sold
- $6.6M
- First sale
- Jan 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$21MraisedJul 2015 · 9 investors · BiotechnologyRule 506(b)
▶$21MraisedJul 2015 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joel SussmanExecutive Officer
- James BarrettDirector
- Michael GutchDirector
- Justin KleinDirector
- Jonathan MowExecutive Officer, Director
- Asish K. XavierDirector
- Clay ThorpDirector
- Guy FishDirector
- Ashutosh ChilkotiDirector
- Robert IngramDirector
- Offering amount
- $42M
- Amount sold
- $21M
- Proceeds to insiders
- $900K
- First sale
- Feb 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
BridgebioBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
Companies working in the same space as PhaseBio Pharmaceuticals.
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $2.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $297.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2006 | $592.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2006 | $100K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $100K |
| National Science Foundation | Phase I | 2003 | $100K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does PhaseBio Pharmaceuticals do?
- PhaseBio is a company focused on developing treatments for cardiovascular disease, which is a leading cause of death in the United States.
- Who founded PhaseBio Pharmaceuticals?
- PhaseBio Pharmaceuticals was founded by Ashutosh Chilkoti.
- Who are PhaseBio Pharmaceuticals's investors?
- PhaseBio Pharmaceuticals's investors include Mountain Group Capital, New Enterprise Associates (NEA), Hatteras Venture Partners, Johnson & Johnson Innovation – JJDC.
- How much funding has PhaseBio Pharmaceuticals raised?
- PhaseBio Pharmaceuticals has disclosed $53.6M raised across 3 of its 5 known rounds.
- Where is PhaseBio Pharmaceuticals headquartered?
- PhaseBio Pharmaceuticals is headquartered in Malvern, US.